

Hong Kong Exchanges and Clearing Limited (“**HKEX**”), The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this document, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this document.

This document, for which we accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Rules**”) for the purpose of giving information with regard to us. We, having made all reasonable enquiries, confirm that to the best of our knowledge and belief the information contained in this document is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this document misleading.

This document is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the Warrants.

The Warrants are complex products. You should exercise caution in relation to them. Investors are warned that the price of the Warrants may fall in value as rapidly as it may rise and holders may sustain a total loss of their investment. Prospective purchasers should therefore ensure that they understand the nature of the Warrants and carefully study the risk factors set out in the Base Listing Document (as defined below) and this document and, where necessary, seek professional advice, before they invest in the Warrants.

The Warrants constitute general unsecured contractual obligations of us as the Issuer and of no other person and will rank equally among themselves and with all our other unsecured obligations (save for those obligations preferred by law) upon liquidation. If you purchase the Warrants, you are relying upon our creditworthiness, and have no rights under the Warrants against the Company which has issued the underlying Shares or any other person. If we become insolvent or default on our obligations under the Warrants, you may not be able to recover all or even part of the amount due under the Warrants (if any).

Non-collateralised Structured Products

Launch Announcement

and

Supplemental Listing Document for Warrants over Single Equities



The Hongkong and Shanghai Banking Corporation Limited

(incorporated in Hong Kong with limited liability under the Companies Ordinance of Hong Kong)

Key Terms

Warrants Stock code	27512	27553	27554
Liquidity Provider Broker ID	9721	9773	9772
Issue size	80,000,000 Warrants	80,000,000 Warrants	150,000,000 Warrants
Style	European style cash settled	European style cash settled	European style cash settled
Type	Call	Call	Call
Company	Hong Kong Exchanges and Clearing Limited	China Life Insurance Company Limited	Ping An Insurance (Group) Company of China, Ltd.
Shares	Existing HKD-traded ordinary issued shares	Existing HKD-traded ordinary issued H shares	Existing HKD-traded ordinary issued H shares
Board Lot	10,000 Warrants	10,000 Warrants	25,000 Warrants
Issue Price per Warrant	HK\$0.15	HK\$0.15	HK\$0.15
Cash Settlement Amount per Board Lot (if any) payable at expiry	<i>For a series of call Warrants:</i> $\frac{\text{Entitlement} \times (\text{Average Price} - \text{Exercise Price}) \times \text{one Board Lot}}{\text{Number of Warrant(s) per Entitlement}}$ <i>For a series of put Warrants:</i> $\frac{\text{Entitlement} \times (\text{Exercise Price} - \text{Average Price}) \times \text{one Board Lot}}{\text{Number of Warrant(s) per Entitlement}}$		
Exercise Price	HK\$450.20	HK\$33.35	HK\$70.04
Average Price ¹ (for all series)	The arithmetic mean of the closing prices of one Share for each Valuation Date		
Entitlement	1 Share	1 Share	1 Share
Number of Warrant(s) per Entitlement	100 Warrants	10 Warrants	50 Warrants
Maximum number of Shares to which the Warrants relate	800,000 Shares	8,000,000 Shares	3,000,000 Shares
Launch Date (for all series)	23 March 2026		
Issue Date (for all series)	25 March 2026		
Listing Date ² (for all series)	26 March 2026		
Valuation Date ³ (for all series)	Each of the five Business Days immediately preceding the Expiry Date		
Expiry Date ⁴	1 September 2026	22 September 2026	18 October 2028
Settlement Date (for all series)	The third CCASS Settlement Day after the later of: (i) the Expiry Date; and (ii) the day on which the Average Price is determined in accordance with the Conditions		
Settlement Currency	Hong Kong dollars	Hong Kong dollars	Hong Kong dollars
Implied Volatility ⁵	30.93%	51.50%	37.36%
Effective Gearing ⁵	6.13x	3.79x	2.97x
Gearing ⁵	26.40x	17.35x	7.67x
Premium ⁵	17.47%	33.94%	34.85%

¹ As derived from the daily quotation sheet of the Stock Exchange, subject to any adjustment to such closing prices as may be necessary to reflect any event as contemplated in Condition 6 such as capitalisation, rights issue, distribution or the like.

² During the period between the Launch Date and the scheduled Listing Date (both dates exclusive), if any event occurs on any Business Day which either results in the Stock Exchange (i) being closed for trading for the entire day; or (ii) being closed prior to its regular time for close of trading for the relevant day, the Listing Date will be postponed (without any further notice or announcement) such that there is a period of two Business Days not affected by the aforementioned event(s) between the Launch Date and the postponed Listing Date (both dates exclusive).

³ Subject to any potential postponement upon the occurrence of a Market Disruption Event, provided that no Valuation Date shall fall on or after the Expiry Date. Please see Condition 4(d) for details.

⁴ If such day is a Saturday, Sunday or public holiday in Hong Kong, the immediately succeeding day which is not a Saturday, Sunday or public holiday in Hong Kong.

⁵ This data may fluctuate during the life of the Warrants and may not be comparable to similar information provided by other issuers of derivative warrants. Each issuer may use different pricing models.

IMPORTANT INFORMATION

The Warrants are listed structured products which involve derivatives. Do not invest in them unless you fully understand and are willing to assume the risks associated with them.

What documents should you read before investing in the Warrants?

You must read this document together with our base listing document dated 1 April 2025 (the “**Base Listing Document**”) as supplemented by any addendum thereto (together, the “**Listing Documents**”), in particular the section “Terms and Conditions of the Equity Warrants (Cash Settled)” (the “**Conditions**”) set out in our Base Listing Document. This document (as read in conjunction with our Base Listing Document and each addendum referred to in the section headed “Product Summary Statement”) is accurate as at the date of this document. You should carefully study the risk factors set out in the Listing Documents. You should also consider your financial position and investment objectives before deciding to invest in the Warrants. We cannot give you investment advice. You must decide whether the Warrants meet your investment needs before investing in the Warrants.

Is there any guarantee or collateral for the Warrants?

No. Our obligations under the Warrants are neither guaranteed by any third party, nor collateralised with any of our assets or other collaterals. When you purchase our Warrants, you are relying on our creditworthiness only, and of no other person. If we become insolvent or default on our obligations under the Warrants, you can only claim as an unsecured creditor of the Issuer. In such event, you may not be able to recover all or even part of the amount due under the Warrants (if any).

What are the Issuer’s credit ratings?

The Issuer’s long-term credit ratings are:

<i>Rating agency</i>	<i>Rating as of the Launch Date</i>
Moody’s Investors Service, Inc.	Aa3 (stable outlook)
S&P Global Ratings	AA- (stable outlook)

Rating agencies usually receive a fee from the companies that they rate. When evaluating our creditworthiness, you should not solely rely on our credit ratings because:

- a credit rating is not a recommendation to buy, sell or hold the Warrants;
- ratings of companies may involve difficult-to-quantify factors such as market competition, the success or failure of new products and markets and managerial competence;
- a high credit rating is not necessarily indicative of low risk. Our credit ratings as of the Launch Date are for reference only. Any downgrading of our ratings could result in a reduction in the value of the Warrants;
- a credit rating is not an indication of the liquidity or volatility of the Warrants; and
- a credit rating may be downgraded if the credit quality of the Issuer declines.

The Warrants are not rated. The Issuer’s credit ratings are subject to change or withdrawal at any time within each rating agency’s sole discretion. You should conduct your own research using publicly available sources to obtain the latest information with respect to the Issuer’s ratings from time to time.

Is the Issuer regulated by the Hong Kong Monetary Authority referred to in Rule 15A.13(2) or the Securities and Futures Commission referred to in Rule 15A.13(3)?

We are a licensed bank regulated by the Hong Kong Monetary Authority, and a registered institution under the Securities and Futures Ordinance (Cap. 571) of Hong Kong to carry on type 1 (Dealing in Securities), type 2 (Dealing in Futures Contracts), type 4 (Advising on Securities), type 5 (Advising on Futures Contracts), type 6 (Advising on Corporate Finance) and type 9 (Asset Management) regulated activities.

Is the Issuer subject to any litigation?

Except as set out in the section headed “Our Interim Financial Statements as at and for the Six-month Period Ended 30 June 2025” of the addendum to our Base Listing Document dated 28 August 2025 (the “**Addendum**”), there are no legal or arbitration proceedings (including any such proceedings which are pending or threatened of which we are aware) which may have, or have had in the previous 12 months, a significant effect on us and our subsidiaries.

Has our financial position changed since last financial year-end?

Except as set out in the section headed “Our Interim Financial Statements as at and for the Six-month Period Ended 30 June 2025” of the Addendum and Exhibit A and Exhibit B of the Base Listing Document, there has been no material adverse change in our financial or trading position or prospects or indebtedness since 31 December 2024.

PRODUCT SUMMARY STATEMENT

The Warrants are listed structured products which involve derivatives. This statement provides you with key information about the Warrants. You should not invest in the Warrants based on the information contained in this statement alone. You should read and understand the remaining sections of this document, together with the other Listing Documents, before deciding whether to invest.

Overview of the Warrants

- **What is a derivative warrant?**

A derivative warrant is an instrument which gives the holder a right to “buy” or “sell” an underlying asset at a pre-set price called the exercise price on or prior to the expiry date. Investing in a derivative warrant does not give you any right in the underlying asset. Derivative warrants usually cost a fraction of the price of the underlying asset and may provide a leveraged return to you. Conversely, such leverage could also magnify your losses.

A call warrant is designed for an investor holding a view that the price of the underlying asset will increase during the term of the warrant.

A put warrant is designed for an investor holding a view that the price of the underlying asset will decrease during the term of the warrant.

- **How and when can you get back your investment?**

The Warrants are European style cash settled derivative warrants linked to the underlying Shares. European style warrants can only be exercised on the expiry date. When the Warrants are exercised, the holder is entitled to a cash amount called the “**Cash Settlement Amount**” net of any Exercise Expenses (as defined under the heading “Exercise Expenses” in the sub-section titled “What are the fees and charges?” below) according to the terms and conditions in the Listing Documents. **If the Cash Settlement Amount is equal to or less than the Exercise Expenses, you will lose all of your investment in the Warrants.**

- **How do the Warrants work?**

The potential payoff at expiry for the Warrants is calculated by reference to the difference between the Exercise Price and the Average Price of the underlying Shares.

A call Warrant will be automatically exercised at expiry without the need for the holder to deliver an exercise notice if the Average Price of the underlying Shares is greater than the Exercise Price. The more the Average Price is above the Exercise Price, the higher the payoff at expiry. If the Average Price is at or below the Exercise Price, you will lose all of your investment in the call Warrant.

A put Warrant will be automatically exercised at expiry without the need for the holder to deliver an exercise notice if the Average Price of the underlying Shares is below the Exercise Price. The more the Average Price is below the Exercise Price, the higher the payoff at expiry. If the Average Price is at or above the Exercise Price, you will lose all of your investment in the put Warrant.

- **Can you sell the Warrants before the Expiry Date?**

Yes. We have made an application for listing of, and permission to deal in, the Warrants on the Stock Exchange. All necessary arrangements have been made to enable the Warrants to be admitted into the Central Clearing and Settlement System (“CCASS”). Issue of the Warrants is conditional upon listing approval being granted. From the Listing Date up to the last trading day of the Warrants (both dates inclusive), you may sell or buy the Warrants on the Stock Exchange. There shall be three CCASS Settlement Days between the last trading day of the Warrants and the Expiry Date. No application has been made to list the Warrants on any other stock exchange.

The Warrants may only be transferred in a Board Lot (or integral multiples thereof). Where a transfer of Warrants takes place on the Stock Exchange, currently settlement must be made not later than two CCASS Settlement Days after such transfer.

The Liquidity Provider will make a market in the Warrants by providing bid and/or ask prices. See the section headed “Liquidity” below.

- **What is your maximum loss?**

The maximum loss in the Warrants will be your entire investment amount plus any transaction costs.

- **What are the factors determining the price of a derivative warrant?**

The price of a derivative warrant generally depends on the price of the underlying asset (being the underlying Shares for the Warrants). However, throughout the term of a derivative warrant, its price will be influenced by a number of factors, including:

- the exercise price of the derivative warrants;
- the value and volatility of the price of the underlying asset (being a measure of the fluctuation in the price of the underlying asset over time);
- the time remaining to expiry: generally, the longer the remaining life of the derivative warrant, the greater its value;
- the interim interest rates and expected dividend payments or other distributions on the underlying asset;
- the liquidity of the underlying asset;
- the supply and demand for the derivative warrant;

- our related transaction cost; and
- the creditworthiness of the issuer of the derivative warrant.

As the price of a derivative warrant is not only affected by the price of the underlying asset, movements in the price of a derivative warrant may not be proportionate or may even be opposite to the price movement of the underlying asset. For example:

- if the price of the underlying asset increases (in respect of a call warrant) or decreases (in respect of a put warrant), but the volatility of the price of the underlying asset decreases, the price of the warrant may decrease;
- if a warrant is deep-out-of-the-money (eg. when the fair market value is less than HK\$0.01), the price of the warrant may be insensitive to any increase (in respect of a call warrant) or decrease (in respect of a put warrant) in the price of the underlying asset;
- if the outstanding volume of a series of warrants in the market is high, the supply and demand of the warrant may have a greater impact on the warrant price than the price of the underlying asset; and/or
- the decrease in time value may offset any increase (in respect of a call warrant) or decrease (in respect of a put warrant) in the price of the underlying asset, especially when the warrant is close to its expiry where the time value decreases at a faster pace.

Risks of investing in the Warrants

You must read the section headed “Key Risk Factors” in this document together with the risk factors set out in our Base Listing Document. You should consider all these factors collectively when making your investment decision.

Liquidity

• How to contact the Liquidity Provider for quotes?

Liquidity Provider: HSBC Securities Brokers (Asia) Limited
 Address: Levels 17 and 18, HSBC Main Building, 1 Queen’s Road Central, Hong Kong
 Telephone Number: (852) 2822 1849

The Liquidity Provider is regulated by the Stock Exchange and the Securities and Futures Commission. It is an affiliate of the Issuer and will act as our agent in providing quotes. You can request a quote by calling the Liquidity Provider at the telephone number above.

- **What is the Liquidity Provider’s maximum response time for a quote?** The Liquidity Provider will respond within 10 minutes and the quote will be displayed on the Stock Exchange’s designated stock page for the Warrants.
- **Maximum spread between bid and ask prices:** 20 spreads
- **Minimum quantity for which liquidity will be provided:** 20 Board Lots
- **What are the circumstances under which the Liquidity Provider is not obliged to provide liquidity?**
 There will be circumstances under which the Liquidity Provider is not obliged to provide liquidity. Such circumstances include:
 - during the first 5 minutes of each morning trading session or the first 5 minutes after trading commences for the first time on a trading day;
 - during a pre-opening session or a closing auction session (if applicable) or any other circumstances as may be prescribed by the Stock Exchange;
 - when the Warrants or the underlying Shares are suspended from trading for any reason;
 - when there are no Warrants available for market making activities. In such event, the Liquidity Provider shall continue to provide bid prices. Warrants held by us or any of our affiliates in a fiduciary or agency capacity are not Warrants available for market making activities;
 - when there are operational and technical problems beyond the control of the Liquidity Provider hindering the ability of the Liquidity Provider to provide liquidity;
 - if the underlying Shares or the stock market experience(s) exceptional price movement and high volatility over a short period of time which materially affects the Liquidity Provider’s ability to source a hedge or unwind an existing hedge; or
 - if the theoretical value of the Warrants is less than HK\$0.01. If the Liquidity Provider chooses to provide liquidity under this circumstance, both bid and ask prices will be made available.

You should read the sub-section entitled “Possible limited secondary market” under the “Key Risk Factors” section for further information on the key risks when the Liquidity Provider is not able to provide liquidity.

How can you obtain further information?

- **Information about the underlying Company and the underlying Shares**

You may obtain information on the underlying Shares (including the underlying Company's financial statements) by visiting the Stock Exchange's website at www.hkex.com.hk or (if applicable) the underlying Company's website(s) as follows:

Underlying Company

Website

Hong Kong Exchanges and Clearing Limited

<http://www.hkexgroup.com/eng/invest/ir.htm>

China Life Insurance Company Limited

<http://www.e-chinalife.com>

Ping An Insurance (Group) Company of China, Ltd.

<http://www.pingan.com>

- **Information about the Warrants after issue**

You may visit our website at <https://www.warrants.hsbc.com.hk/en/warrant/latest-document-and-notice> to obtain information on the Warrants or any notice given by us in relation to the Warrants.

- **Information about us**

You should read the section "Updated Information about Us" in this document. You may visit www.hsbc.com.hk to obtain general corporate information about us.

We have included references to websites in this document to indicate how further information may be obtained. Information appearing on those websites does not form part of the Listing Documents. We accept no responsibility for the accuracy or completeness of the information appearing on those websites. You should conduct your own due diligence (including without limitation web searches) to ensure that you are viewing the most up-to-date information.

What are the fees and charges?

- **Trading Fees and Levies**

For each transaction effected on the Stock Exchange, the following trading fees and levies calculated on the value of the consideration for the Warrants will be payable by each of the seller and the buyer:

- (i) a trading fee of 0.00565 per cent. charged by the Stock Exchange;
- (ii) a transaction levy of 0.0027 per cent. charged by the Securities and Futures Commission; and
- (iii) a transaction levy of 0.00015 per cent. charged by the Accounting and Financial Reporting Council.

The levy for the investor compensation fund is currently suspended.

- **Exercise Expenses**

You are responsible for any Exercise Expenses. Exercise Expenses mean any charges or expenses including any taxes or duties which are incurred in respect of the exercise of the Warrants. Any Exercise Expenses will be deducted from the Cash Settlement Amount (if any). If the Cash Settlement Amount is equal to or less than the Exercise Expenses, no amount is payable. As at the date of this document, no Exercise Expenses are payable for cash settled warrants (including the Warrants).

- **Stamp Duty**

No stamp duty is currently payable in Hong Kong on transfer of cash settled warrants (including the Warrants).

You should note that any transaction cost will reduce your gain or increase your loss under your investment in the Warrants.

What is the legal form of the Warrants?

Each series of the Warrants will be represented by a global certificate in the name of HKSCC Nominees Limited who is the only legal owner of the Warrants. We will not issue definitive certificates for the Warrants. You may arrange for your broker to hold the Warrants in a securities account on your behalf, or if you have a CCASS Investor Participant securities account, you may arrange for the Warrants to be held in such account. You will have to rely on the records of CCASS and/or the statements you receive from your brokers as evidence of your beneficial interest in the Warrants.

Can we adjust the terms of the Warrants?

The occurrence of certain events (including, without limitation, a rights issue, bonus issue or cash distribution by the Company, a subdivision or consolidation of the underlying Shares or a restructuring event affecting the Company) may entitle us to adjust the terms and conditions of the Warrants. However, we are not obliged to adjust the terms and conditions of the Warrants for every event that affects the underlying Shares.

Please refer to Conditions 6 and 14 for details about adjustments. Such events may negatively affect your investment and you may suffer a loss.

Can the Warrants be early terminated?

The Warrants will terminate automatically in the event of liquidation, dissolution or winding up of the Company or the appointment of a liquidator, receiver or administrator in respect of the Company's undertaking, property or assets, save in the case of put Warrants, whereby if we determine that there is any residual value in the relevant put Warrant upon the occurrence of such insolvency event, we will pay you the residual value of such put Warrant in cash representing the fair market value of such put Warrant less our costs of unwinding any related hedging arrangements and any related charges or expenses as determined by us. We may also early terminate the Warrants if it becomes illegal or impracticable for us (i) to perform our obligations under the Warrants as a result of a change in law event, or (ii) to maintain our hedging arrangement with respect to the Warrants due to a change in law event. In such case, we will pay you a cash amount representing the fair market value of the Warrants less our costs of unwinding any related hedging arrangements and related charges or expenses, as determined by us. In either case, the amount payable by us (if any) may be substantially less than your initial investment and may be zero.

Please refer to Conditions 7 and 12 for details about early termination events. Such events may negatively affect your investment and you may suffer a loss.

Mode of settlement for the Warrants

The Warrants will be automatically exercised on the Expiry Date in integral multiples of the Board Lot if the Cash Settlement Amount is positive. If the Cash Settlement Amount is zero or negative, or is equal to or less than the Exercise Expenses, you will lose all of your investment.

We will deliver a cash amount in the Settlement Currency equal to the Cash Settlement Amount net of any Exercise Expenses (if any) no later than the Settlement Date to HKSCC Nominees Limited (as the registered holder of the Warrants), which will then distribute such amount to the securities account of your broker (and if applicable, its custodian) or to your CCASS Investor Participant securities account (as the case may be). You may have to rely on your broker (and if applicable, its custodian) to ensure that the Cash Settlement Amount (if any) is credited to your account maintained with your broker. Once we make the payment to HKSCC Nominees Limited, who operates CCASS, you will have no further right against us for that payment, even if CCASS or your broker (and if applicable, its custodian) does not transfer your share of payment to you, or is late in making such payment transfer.

Payment of the Cash Settlement Amount (if any) may be delayed if a Settlement Disruption Event occurs on the Settlement Date, as a result of which we are unable to deliver such amount through CCASS on such day. See Condition 4(d) for further information.

Where can you find the relevant documents of the Warrants?

The following documents are available on the website of the HKEX at www.hkexnews.hk and our website at <https://www.warrants.hsbc.com.hk/en/warrant/latest-document-and-notice>:

以下文件可於香港交易所披露易網站(www.hkexnews.hk) 以及本公司網站<https://www.warrants.hsbc.com.hk/zh/warrant/latest-document-and-notice> 瀏覽：

- each of the Listing Documents (in separate English and Chinese versions), including:
 - this document
 - our Base Listing Document
 - the Addendum
- our latest audited consolidated financial statements and any interim or quarterly financial statements;
- a copy of the consent letter of our auditors referred to in our Base Listing Document.

Are there any dealings in the Warrants before the Listing Date?

It is possible that there may have been dealings in the Warrants before the Listing Date. If there are any dealings in the Warrants by us or any of our subsidiaries or associated companies from the Launch Date prior to the Listing Date, we will report those dealings to the Stock Exchange by the Listing Date and such report will be released on the website of the Stock Exchange.

Has the auditor consented to the inclusion of its report to the Listing Documents?

Our auditor ("Auditor") has given and has not since withdrawn its written consent to the inclusion of its report dated 19 February 2025 and/or the references to its name in our Base Listing Document, in the form and context in which they are included. Its report was not prepared exclusively for incorporation into our Base Listing Document. The Auditor does not own any of our shares or shares in any member of our group, nor does it have the right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for our securities or securities of any member of our group.

Authorisation of the Warrants

The issue of the Warrants has been approved in accordance with our product governance policy since 2005.

Selling restrictions

The Warrants have not been and will not be registered under the United States Securities Act of 1933, as amended (the “**Securities Act**”), and will not be offered, sold, delivered or traded, at any time, indirectly or directly, in the United States or to, or for the account or benefit of, (a) a U.S. Person (as defined in Regulation S of the Securities Act), (b) a U.S. person as defined in 17 C.F.R. § 23.23(a)(23) (a “**CFTC U.S. Person**”) or to others for offer or sale to or for the account or benefit of any such CFTC U.S. person or (c) a “United States person” as defined in U.S. Executive Order 13959, as amended by U.S. Executive Order 14032, or in the Chinese Military-Industrial Complex Sanctions Regulations (31 C.F.R. Part 586) (“**E.O. 13959 U.S. Persons**”), to the extent that the underlyings for the relevant Warrants include (i) securities whose purchase or sale by E.O. 13959 U.S. Persons is restricted under Executive Order 13959 (as amended) or (ii) provide any investment exposure to any such securities ((i) and (ii) collectively, “**E.O. 13959 Restricted Underlyings**”).

E.O. 13959 U.S. Persons are restricted from purchasing or selling Warrants with E.O. 13959 Restricted Underlyings after the effective date of the Executive Order 13959 (as amended) restrictions applicable to those underlyings and investors should seek their own independent legal advice regarding compliance with Executive Order 13959 (as amended).

The offer or transfer of the Warrants is also subject to the selling restrictions specified in our Base Listing Document.

Capitalised terms and inconsistency

Unless otherwise specified, capitalised terms used in this document have the meanings set out in the Conditions. If this document is inconsistent with our Base Listing Document, this document shall prevail.

KEY RISK FACTORS

You must read these key risk factors together with the risk factors set out in our Base Listing Document. These key risk factors do not necessarily cover all risks related to the Warrants. If you have any concerns or doubts about the Warrants, you should obtain independent professional advice.

Non-collateralised structured products

The Warrants are not secured on any of our assets or any collateral.

Credit risk

If you invest in the Warrants, you are relying on our creditworthiness and of no other person (including the ultimate holding company of our group, HSBC Holdings plc). If we become insolvent or default on our obligations under the Warrants, you can only claim as unsecured creditor regardless of the performance of the underlying Shares and you may not be able to recover all or even part of the amount due under the Warrants (if any). You have no rights under the terms of the Warrants against the Company.

Warrants are not principal protected and may expire worthless

Although the cost of a Warrant may cost a fraction of the value of the underlying Shares, the Warrant's price may change more rapidly than the price of the underlying Shares. Given the gearing feature inherent in the Warrants, a small change in the price of the underlying Shares may lead to a substantial price movement in the Warrants. You may suffer higher losses in percentage terms if you expect the price of the underlying Shares to move one way but it moves in the opposite direction.

Unlike stocks, the Warrants have a limited life and will expire on the Expiry Date. In the worst case, the Warrants may expire with no value and you will lose all of your investment. Derivative warrants may only be suitable for experienced investors who are willing to accept the risk that they may lose all their investment.

The Warrants can be volatile

Prices of the Warrants may rise or fall rapidly. You should carefully consider, among other things, the following factors before dealing in the Warrants:

- (i) the prevailing trading price of the Warrants;
- (ii) the Exercise Price of the Warrants;
- (iii) the value and volatility of the price of the underlying Shares;
- (iv) the time remaining to expiry;
- (v) the probable range of the Cash Settlement Amount;
- (vi) the interim interest rates and expected dividend payments or other distributions on the underlying Shares;
- (vii) the liquidity of the underlying Shares;
- (viii) the related transaction costs (including the Exercise Expenses, if any);
- (ix) the supply and demand for the Warrants; and
- (x) the creditworthiness of the Issuer.

The price of a Warrant may be affected by all these factors in addition to the trading price of the underlying Shares. Therefore, movements in the price of the Warrants may not be proportionate or may even be opposite to the price movement of the underlying Shares. You should consider all these factors collectively when making your investment decision.

Time decay

Without taking into account interim interest rates and expected dividend payments or other distributions on the underlying Shares and assuming all other factors remain constant, the value of a Warrant is likely to decrease over time. Therefore, the Warrants should not be viewed as a product for long term investments.

Not the same as investing in the underlying Shares

Investing in the Warrants is not the same as investing in the underlying Shares. You have no rights in the underlying Shares throughout the term of the Warrants. Changes in the market value of the Warrants may not correspond with the movements in the price of the underlying Shares, especially when the theoretical value of the Warrants is at HK\$0.01 or below. If you buy the Warrants with a view to hedge against your exposure to the underlying Shares, it is possible that you could suffer loss in your investment in the underlying Shares and the Warrants.

Suspension of trading

If trading in the underlying Shares is suspended on the Stock Exchange, trading in the Warrants may be suspended for a similar period. In the case of a prolonged suspension period, the price of the Warrants may be subject to a significant impact of time decay due to such prolonged suspension and may fluctuate significantly upon resumption of trading, which may adversely affect your investment.

Possible limited secondary market

The Liquidity Provider may be the only market participant for the Warrants and therefore the secondary market for the Warrants may be limited. The more limited the secondary market, the more difficult it may be for you to realise the value in the Warrants prior to expiry.

You should also be aware that the Liquidity Provider may not be able to provide liquidity when there are operational and technical problem hindering its ability to do so. Even if the Liquidity Provider is able to provide liquidity in such circumstances, its performance of liquidity provision may be adversely affected. For example:

- (i) the spread between bid and ask prices quoted by the Liquidity Provider may be significantly wider than its normal standard;
- (ii) the quantity for which liquidity will be provided by the Liquidity Provider may be significantly smaller than its normal standard; and/or
- (iii) the Liquidity Provider's response time for a quote may be significantly longer than its normal standard.

Adjustment related risk

The occurrence of certain events (including, without limitation, a rights issue, bonus issue or cash distribution by the Company, a subdivision or consolidation of the underlying Shares and a restructuring event affecting the Company) may entitle us to adjust the terms and conditions of the Warrants. However, we are not obliged to adjust the terms and conditions of the Warrants for every event that affects the underlying Shares. Any adjustment or decision not to make any adjustment may adversely affect the value of the Warrants. Please refer to Conditions 6 and 14 for details about adjustments.

Possible early termination

The Warrants will terminate automatically in the event of liquidation, dissolution or winding up of the Company or the appointment of a liquidator, receiver or administrator in respect of the Company's undertaking, property or assets, save in the case of put Warrants, whereby if we determine that there is any residual value in the relevant put Warrant upon the occurrence of such insolvency event, we will pay you the residual value of such put Warrant in cash representing the fair market value of such put Warrant less our costs of unwinding any related hedging arrangements and any related charges or expenses as determined by us.

We may also early terminate the Warrants if it becomes illegal or impracticable for us (i) to perform our obligations under the Warrants as a result of a change in law event, or (ii) to maintain our hedging arrangement with respect to the Warrant due to a change in law event. In such case, we will pay you a cash amount representing the fair market value of the Warrants less our costs of unwinding any related hedging arrangements and related charges or expenses, as determined by us.

In either case, the amount payable by us (if any) may be substantially less than your initial investment and may be zero. Please refer to Conditions 7 and 12 for details about our early termination rights.

Time lag between exercise and settlement of the Warrants

There is a time lag between exercise of the Warrants and payment of the Cash Settlement Amount net of Exercise Expenses (if any). There may be delays in the electronic settlement or payment through CCASS.

Conflict of interest

We and our subsidiaries and affiliates engage in a wide range of commercial and investment banking, brokerage, funds management, hedging, investment and other activities and may possess material information about the Company and/or the underlying Shares or issue or update research reports on the Company and/or the underlying Shares. Such activities, information and/or research reports may involve or affect the Company and/or the underlying Shares and may cause consequences adverse to you or otherwise create conflicts of interests in connection with the issue of the Warrants. We have no obligation to disclose such information and may issue research reports and engage in any such activities without regard to the issue of the Warrants.

In the ordinary course of our business, we and our subsidiaries and affiliates may effect transactions for our own account or for the account of our customers and may enter into one or more transactions with respect to the Company and/or the underlying Shares or related derivatives. This may indirectly affect your interests.

We and/or members of our group (acting as a dealer) may offer commission rebates or other incentives

We and/or members of our group may, from time to time, act in the capacity of a dealer of the Warrants. When acting in such capacity, we and/or members of our group may, in the ordinary course of our/their business, offer commission rebates or other incentives to our/their customers in respect of the Warrants. Your investment decision should not be based solely on the benefit of the offer of such commission rebates or other incentives. Before deciding to invest in the Warrants, you should fully understand the nature and product features of the Warrants and read the Listing Documents, in particular, the risk factors set out in the Listing Documents and where necessary, seek independent professional advice. You should also consider your financial position and investment objectives before deciding to invest in the Warrants.

No direct contractual rights

The Warrants are issued in global registered form and are held within CCASS. You will not receive any definitive certificate and your name will not be recorded in the register of the Warrants. The evidence of your interest in the Warrants, and the efficiency of the ultimate payment of the Cash Settlement Amount net of Exercise Expenses (if any), are subject to the CCASS Rules. You will have to rely on your broker (or, if applicable, its direct or indirect custodians) and the statements you receive from it as evidence of your interest in the Warrants. You do not have any direct contractual rights against us. To assert your rights as an investor in the Warrants, you will have to rely on your broker (and, if applicable, its direct or indirect custodian) to take action on your behalf. If your broker or, if applicable, its direct or indirect custodian:

- (i) fails to take action in accordance with your instructions;
- (ii) becomes insolvent; or
- (iii) defaults on its obligations,

you will need to take action against your broker in accordance with the terms of arrangement between you and your broker to establish your interest in the Warrants first before you can assert your right of claim against us. You may experience difficulties in taking such legal proceedings. This is a complicated area of law and you should seek independent legal advice for further information.

Risk related to Shares of the underlying Company adopting the multiple counters model

Where the underlying Shares are traded in both Renminbi ("RMB") and HKD under the Stock Exchange's multiple counters model, you need to consider the following additional risks in light of the novelty and relatively untested nature of the Stock Exchange's multiple counters model:

- (a) the Warrants are linked to the HKD-traded Shares of the underlying Company only. Movements in the trading prices of the RMB-traded Shares of the underlying Company should not directly affect the price of the Warrants;
- (b) if there is a suspension of inter-counter transfer of such Shares of the underlying Company between the HKD counter and the RMB counter for any reason, such Shares of the underlying Company will only be able to be traded in the relevant currency counter on the Stock Exchange, which may affect the demand and supply of such Shares of the underlying Company and have an adverse effect on the price of the Warrants; and
- (c) the trading prices on the Stock Exchange of the HKD-traded Shares of the underlying Company may deviate significantly from the trading prices on the Stock Exchange of the RMB-traded Shares of the underlying Company due to different factors, such as market liquidity, foreign exchange conversion risk, supply and demand in each counter and exchange rate fluctuation. Changes in the trading price of the HKD-traded Shares of the underlying Company may adversely affect the price of the Warrants.

The Listing Documents should not be relied upon as the sole basis for your investment decision

The Listing Documents do not take into account your investment objectives, financial situation or particular needs. Nothing in the Listing Documents should be construed as a recommendation by us or our affiliates to invest in the Warrants or the underlying Shares.

Not the ultimate holding company of the group

We are not the ultimate holding company of the group to which we belong. The ultimate holding company of the group to which we belong is HSBC Holdings plc.

Credit ratings

Our credit ratings as of the Launch Date are for reference only. Any downgrading of our ratings could result in a reduction in the value of the Warrants.

Two or more risk factors may simultaneously affect the Warrants

Two or more risk factors may simultaneously have an effect on the value of a Warrant such that the effect of any individual risk factor may not be predicted. No assurance can be given as to the effect any combination of risk factors may have on the value of a Warrant.

The Financial Institutions (Resolution) Ordinance may adversely affect the Warrants

On 7 July 2017, the Financial Institutions (Resolution) Ordinance (Cap. 628) of Hong Kong (the “**FIRO**”) came into operation. The FIRO provides for, among other things, the establishment of a resolution regime for authorized institutions and other within scope financial institutions in Hong Kong which may be designated by the relevant resolution authorities, which includes us as the issuer of the Warrants. The resolution regime seeks to provide the relevant resolution authorities with administrative powers to bring about timely and orderly resolution in order to stabilise and secure continuity for a failing authorized institution or within scope financial institution in Hong Kong. In particular, the relevant resolution authority is provided with powers to affect contractual and property rights as well as payments (including in respect of any priority of payment) that creditors would receive in resolution. These may include, but are not limited to, powers to cancel, write off, modify, convert or replace all or a part of the Warrants or cash payment under the Warrants, and powers to amend or alter the contractual provisions of the Warrants, all of which may adversely affect the value of the Warrants, and the holders thereof may suffer a loss of some or all of their investment as a result. Holders of the Warrants may become subject to and bound by the FIRO.

On 25 June 2021, the government of Hong Kong published the Financial Institutions (Resolution) (Contractual Recognition of Suspension of Termination Rights – Banking Sector) Rules (the “**Stay Rules**”) in the Gazette. The Stay Rules have come into operation on 27 August 2021 following completion of the vetting process by the Legislative Council of Hong Kong. Subject to certain transitional periods, entities subject to the Stay Rules are required to adopt appropriate provisions in certain financial contracts to the effect that the contractual parties agree to be bound by the temporary stay that may be imposed by the Hong Kong Monetary Authority under the FIRO, which may in turn affect any in-scope financial contracts between a qualifying entity and its counterparty(ies).

As the implementation of FIRO remains untested and certain details relating to FIRO will be set out through secondary legislation and supporting rules, we are unable to assess the full impact of FIRO, the Stay Rules, any potential secondary legislation and/or supporting rules and regulations made under FIRO on the financial system generally, our counterparties, us, any of our consolidated subsidiaries, our operations and/or our financial position. **In the worst case scenario, you may get nothing back and the maximum loss could be 100% of your initial investment amount.**

Recent and future U.S. government actions

The US government’s recent and future actions against mainland China and Hong Kong may affect the price or value of the underlying equities or indices (as applicable) and the prevailing trading price of the Warrants. There can be no assurances that any future actions taken by the U.S. government (or other governments) against mainland China and Hong Kong will not have an adverse effect on the trading price or value of the Warrants.

Restrictions on E.O. 13959 U.S. Persons

To the extent the Warrants include underlying securities that are or become E.O. 13959 Restricted Underlyings, E.O. 13959 U.S. Persons are or will be restricted under Executive Order 13959 (as amended) from purchasing and selling the Warrants, which may adversely affect the prevailing trading price of the Warrants. E.O. 13959 U.S. Persons are urged to seek independent legal advice regarding compliance with Executive Order 13959 (as amended).

Updated information about Us

On 9 October 2025, HSBC Holdings plc, the Issuer and Hang Seng Bank Limited (“**Hang Seng Bank**”) published a joint announcement in relation to (1) proposal for the privatisation of Hang Seng Bank by the Issuer by way of a scheme of arrangement under section 673 of the Companies Ordinance, (2) proposed withdrawal of listing of Hang Seng Bank shares and (3) discloseable transaction of HSBC Holdings plc in relation to the proposal. Investors can view further information on this on <https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1009/2025100900165.pdf>.

Ms Jolene HO has replaced Ms Queenie LUN as the authorised representative of the Issuer with effect from 11 December 2025.

On 15 December 2025, HSBC Holdings plc, the Issuer and Hang Seng Bank announced the despatch of the scheme document regarding the proposal for the privatisation of Hang Seng Bank by way of a scheme of arrangement (the “**Scheme**” and together the “**Scheme Document**”). Subject to satisfaction or (if applicable) waiver of the conditions described in the Scheme Document, including approval by the shareholders of Hang Seng Bank and the sanction of the Scheme by the High Court of Hong Kong, the Scheme is expected to become binding and effective on 26 January 2026. For further information, please see the Scheme Document at <https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1215/2025121500035.pdf>.

On 8 January 2026, (i) the resolution to approve the Scheme was approved at a meeting of shareholders of Hang Seng Bank convened at the direction of the High Court of Hong Kong; and (ii) the special resolution to approve and give effect to the proposal for the privatisation of Hang Seng Bank by the Issuer by way of the Scheme and the withdrawal of the listing of the Hang Seng Bank shares and the Scheme, was approved at a general meeting of Hang Seng Bank.

With effect from 8 January 2026, the issued and fully paid-up share capital of the Issuer has been increased by an allotment of 17,448,928,000 new ordinary shares to HSBC Asia Holdings Limited, the current sole shareholder of the Issuer, for a total consideration of HK\$43,622,320,000.

Following the change, the issued and fully paid-up ordinary share capital of the Issuer is HK\$167,570,799,495 and US\$7,198,000,000 comprising 67,028,319,798 ordinary shares.

With effect from 26 January 2026, the Bank Group’s interest in issued share capital of Hang Seng Bank is 100 per cent.

With effect from 4 p.m. on 27 January 2026, the listing of Hang Seng Bank shares has been withdrawn.

Waiver from compliance with the Rules

The Issuer has applied for, and the Stock Exchange has granted, a waiver from compliance with Rule 15A.24A of the Rules in respect of securities promotional campaigns (the “**Incentive**”) offered by the Retail Banking and Wealth Division of the Issuer for the period from 1 January 2026 to 31 December 2026 (the “**Waiver**”).

The Incentive is applicable equally under the same terms to all listed securities regardless of product type or issuer. Any incentives given by the Retail Banking and Wealth Division of the Issuer will not be recovered (directly or indirectly) from the Global Banking and Markets Division of the Issuer which operates the structured products business.

The Waiver is granted subject to the following conditions:

- (a) the inclusion of a risk factor in supplemental listing documents and a reminder to investors in all marketing materials of the Incentive. The risk factor and the reminder to investors should contain the following:
 - (i) a statement to the effect that the Incentive is offered as part of the ordinary course of business of the Issuer’s securities business; and
 - (ii) a reminder to investors to the effect that they should focus their assessment on product features of the structured products and assess the risks against their investment objectives before making investment decisions, without regard to the benefit of the Incentive.
- (b) the disclosure of details of the Waiver granted in this document and/or the Base Listing Document.

Pursuant to the Waiver, a risk factor entitled “We and/or members of our group (acting as a dealer) may offer commission rebates or other incentives” under the section headed “Key Risk Factors” is included in this document.

Annual Report and Accounts

The Issuer published its Annual Report and Accounts on 11 March 2026. Selected relevant parts of the Annual Report and Accounts dated 11 March 2026 are set out below. The selected relevant parts of the Annual Report and Accounts are not complete and reference should be made to the full Annual Report and Accounts which are available at <https://www.hsbc.com/-/files/hsbc/investors/hsbc-results/2025/annual/pdfs/the-hongkong-and-shanghai-banking-corporation-limited/260311-annual-report-and-accounts-2025-en.pdf>.

Consolidated Financial Statements

Consolidated income statement

for the year ended 31 December

	Notes	2025 HK\$m	2024 HK\$m
Net interest income	2a	128,403	117,637
– interest income		285,202	315,868
– interest expense		(156,799)	(198,231)
Net fee income	2b	50,551	42,517
– fee income		65,641	56,219
– fee expense		(15,090)	(13,702)
Net income from financial instruments held for trading or managed on a fair value basis	2c	85,054	91,930
Net income from assets and liabilities of insurance businesses, including related derivatives, measured at fair value through profit or loss	2c	76,017	36,024
Insurance finance expense		(75,650)	(35,663)
Insurance service result	3	11,998	8,131
– Insurance revenue		20,886	16,533
– Insurance service expense		(8,888)	(8,402)
Other operating income/(expense) ¹	2d	(1,622)	5,119
Net operating income before change in expected credit losses and other credit impairment charges		274,751	265,695
Change in expected credit losses and other credit impairment charges	2e	(12,752)	(11,946)
Net operating income		261,999	253,749
Employee compensation and benefits	4	(41,562)	(40,028)
General and administrative expenses	2f	(62,208)	(57,967)
Depreciation and impairment of property, plant and equipment	2g	(7,181)	(10,925)
Amortisation and impairment of intangible assets		(9,929)	(8,672)
Total operating expenses		(120,880)	(117,592)
Operating profit		141,119	136,157
Share of profit in associates and joint ventures	14	16,761	17,775
Impairment of interest in associate ¹	14	(8,270)	—
Profit before tax		149,610	153,932
Tax expense	5	(25,493)	(24,681)
Profit for the year		124,117	129,251
Attributable to:			
– ordinary shareholders of the parent company		112,982	118,787
– other equity holders		5,304	3,576
– non-controlling interests		5,831	6,888
Profit for the year		124,117	129,251

¹ The amount in 'Other operating income/(expense)' includes a loss of HK\$8,955m inclusive of reserves recycling, recorded in 2025 as a result of the dilution of our shareholding in BoCom. We have also recognised a HK\$8,270m impairment loss following an impairment test on the carrying amount of the group's investment in BoCom in 'Impairment of interest in associate'. Further details are set out in Note 14 'Interests in associates and joint ventures'.

Consolidated Financial Statements

Consolidated statement of comprehensive income for the year ended 31 December

	2025 HK\$m	2024 HK\$m
Profit for the year	124,117	129,251
Other comprehensive income/(expense)		
Items that will be reclassified subsequently to profit or loss when specific conditions are met:		
Debt instruments at fair value through other comprehensive income	8,443	(183)
– fair value gains	10,571	173
– fair value gains transferred to the income statement	(458)	(52)
– expected credit (recoveries)/losses recognised in the income statement	(31)	49
– income taxes	(1,639)	(353)
Cash flow hedges	4,445	(1,156)
– fair value (losses)/gains	(1,334)	15,398
– fair value losses/(gains) reclassified to the income statement	6,668	(16,764)
– income taxes	(889)	210
Share of other comprehensive income of associates and joint ventures	(225)	2,978
– other comprehensive income reclassified to the income statement on disposal or dilution of foreign operations	(439)	—
– share for the year	214	2,978
Exchange differences	18,540	(18,086)
– foreign exchange losses reclassified to income statement on disposal or dilution of foreign operations	1,539	—
– other exchange differences	17,001	(18,086)
Items that will not be reclassified subsequently to profit or loss:		
Property revaluation	(1,845)	(203)
– fair value losses	(2,252)	(271)
– income taxes	407	68
Equity instruments designated at fair value through other comprehensive income	604	790
– fair value gains	811	974
– income taxes	(207)	(184)
Changes in fair value of financial liabilities designated at fair value upon initial recognition arising from changes in own credit risk	(1,235)	(2,365)
– before income taxes	(1,485)	(2,831)
– income taxes	250	466
Remeasurement of defined benefit asset/liability	170	685
– before income taxes	194	812
– income taxes	(24)	(127)
Other comprehensive income/(expense) for the year, net of tax	28,897	(17,540)
Total comprehensive income for the year	153,014	111,711
Attributable to:		
– ordinary shareholders of the parent company	140,921	101,367
– other equity holders	5,304	3,576
– non-controlling interests	6,789	6,768
Total comprehensive income for the year	153,014	111,711

Consolidated Financial Statements

Consolidated balance sheet at 31 December

	Notes	31 Dec 2025 HK\$m	31 Dec 2024 HK\$m
Assets			
Cash and balances at central banks		204,345	211,047
Hong Kong Government certificates of indebtedness		342,994	328,454
Trading assets	7	1,223,430	1,085,321
Derivatives	8	398,946	505,260
Financial assets designated and otherwise mandatorily measured at fair value through profit or loss	9	924,722	781,210
Reverse repurchase agreements – non-trading		885,669	816,102
Loans and advances to banks		516,658	480,740
Loans and advances to customers	10	3,641,752	3,494,298
Financial investments	11	2,537,975	2,337,844
Amounts due from Group companies	31	192,443	175,004
Interests in associates and joint ventures	14	178,839	178,330
Goodwill and intangible assets	15	42,638	41,308
Property, plant and equipment	16	116,262	120,774
Deferred tax assets	5	17,803	10,307
Prepayments, accrued income and other assets	17	458,755	382,941
Total assets		11,683,231	10,948,940
Liabilities			
Hong Kong currency notes in circulation		342,994	328,454
Repurchase agreements – non-trading		622,751	624,784
Deposits by banks		232,930	183,612
Customer accounts	18	7,097,003	6,564,606
Trading liabilities	19	88,404	86,557
Derivatives	8	418,974	473,488
Financial liabilities designated at fair value	20	195,199	178,739
Debt securities in issue	21	47,020	64,362
Retirement benefit liabilities	4	811	805
Amounts due to Group companies	31	387,744	396,356
Accruals and deferred income, other liabilities and provisions	22	320,213	339,713
Insurance contract liabilities	3	943,838	799,443
Current tax liabilities		16,670	7,096
Deferred tax liabilities	5	24,509	22,917
Total liabilities		10,739,060	10,070,932
Equity			
Share capital	23	180,181	180,181
Other equity instruments	24	79,158	64,677
Other reserves		136,194	102,993
Retained earnings		489,040	471,198
Total shareholders' equity		884,573	819,049
Non-controlling interests		59,598	58,959
Total equity		944,171	878,008
Total liabilities and equity		11,683,231	10,948,940

Consolidated Financial Statements

Consolidated statement of changes in equity

for the year ended 31 December

	Other reserves								Total share-holders' equity	Non-controlling interests	Total equity
	Share capital ¹	Other equity instruments	Retained earnings	Property revaluation reserve	Financial assets at FVOCI reserve	Cash flow hedge reserve	Foreign exchange reserve	Other ⁴			
	HK\$m	HK\$m	HK\$m	HK\$m	HK\$m	HK\$m	HK\$m	HK\$m	HK\$m	HK\$m	HK\$m
At 1 Jan 2025	180,181	64,677	471,198	61,204	424	710	(65,392)	106,047	819,049	58,959	878,008
Profit for the year	—	—	118,286	—	—	—	—	—	118,286	5,831	124,117
Other comprehensive income/(expense) (net of tax)	—	—	(1,077)	(1,642)	9,098	3,887	17,648	25	27,939	958	28,897
– debt instruments at fair value through other comprehensive income	—	—	—	—	8,266	—	—	—	8,266	177	8,443
– equity instruments designated at fair value through other comprehensive income	—	—	—	—	497	—	—	—	497	107	604
– cash flow hedges	—	—	—	—	—	3,875	—	—	3,875	570	4,445
– changes in fair value of financial liabilities designated at fair value upon initial recognition arising from changes in own credit risk	—	—	(1,232)	—	—	—	—	—	(1,232)	(3)	(1,235)
– property revaluation	—	—	—	(1,642)	—	—	—	—	(1,642)	(203)	(1,845)
– remeasurement of defined benefit asset/liability	—	—	127	—	—	—	—	—	127	43	170
– share of other comprehensive income of associates and joint ventures	—	—	28	—	161	—	—	25	214	—	214
– other comprehensive income reclassified to the income statement on disposal or dilution of foreign operations	—	—	—	—	(439)	—	—	—	(439)	—	(439)
– foreign exchange losses reclassified to income statement on disposal or dilution of foreign operations	—	—	—	—	—	—	1,539	—	1,539	—	1,539
– exchange differences	—	—	—	—	613	12	16,109	—	16,734	267	17,001
Total comprehensive income/(expense) for the year	—	—	117,209	(1,642)	9,098	3,887	17,648	25	146,225	6,789	153,014
Other equity instruments issued ²	—	31,686	—	—	—	—	—	—	31,686	—	31,686
Other equity instruments redeemed ³	—	(17,205)	—	—	—	—	—	—	(17,205)	—	(17,205)
Dividends to shareholders ⁵	—	—	(94,104)	—	—	—	—	—	(94,104)	(4,906)	(99,010)
Movement in respect of share-based payment arrangements	—	—	(408)	—	—	—	—	(529)	(937)	13	(924)
Transfers and other movements ⁶	—	—	(4,855)	(1,776)	131	(19)	—	6,378	(141)	(1,257)	(1,398)
At 31 Dec 2025	180,181	79,158	489,040	57,786	9,653	4,578	(47,744)	111,921	884,573	59,598	944,171

Consolidated Financial Statements

Consolidated statement of changes in equity (continued)

for the year ended 31 December

	Other reserves								Total share-holders' equity	Non-controlling interests	Total equity
	Share capital ¹	Other equity instruments	Retained earnings	Property revaluation reserve	Financial assets at FVOCI reserve	Cash flow hedge reserve	Foreign exchange reserve	Other ⁴			
	HK\$m	HK\$m	HK\$m	HK\$m	HK\$m	HK\$m	HK\$m	HK\$m	HK\$m	HK\$m	HK\$m
At 1 Jan 2024	180,181	52,465	462,866	65,279	(2,546)	1,851	(47,899)	100,529	812,726	59,860	872,586
Profit for the year	—	—	122,363	—	—	—	—	—	122,363	6,888	129,251
Other comprehensive income/(expense) (net of tax)	—	—	(1,796)	23	2,962	(1,140)	(17,493)	24	(17,420)	(120)	(17,540)
– debt instruments at fair value through other comprehensive income	—	—	—	—	(289)	—	—	—	(289)	106	(183)
– equity instruments designated at fair value through other comprehensive income	—	—	—	—	605	—	—	—	605	185	790
– cash flow hedges	—	—	—	—	—	(1,136)	—	—	(1,136)	(20)	(1,156)
– changes in fair value of financial liabilities designated at fair value upon initial recognition arising from changes in own credit risk	—	—	(2,364)	—	—	—	—	—	(2,364)	(1)	(2,365)
– property revaluation	—	—	—	23	—	—	—	—	23	(226)	(203)
– remeasurement of defined benefit asset/liability	—	—	561	—	—	—	—	—	561	124	685
– share of other comprehensive income of associates and joint ventures	—	—	7	—	2,947	—	—	24	2,978	—	2,978
– other comprehensive income reclassified to the income statement on disposal or dilution of foreign operations	—	—	—	—	—	—	—	—	—	—	—
– foreign exchange losses reclassified to income statement on disposal or dilution of foreign operations	—	—	—	—	—	—	—	—	—	—	—
– exchange differences	—	—	—	—	(301)	(4)	(17,493)	—	(17,798)	(288)	(18,086)
Total comprehensive income/(expense) for the year	—	—	120,567	23	2,962	(1,140)	(17,493)	24	104,943	6,768	111,711
Other equity instruments issued ²	—	27,873	—	—	—	—	—	—	27,873	—	27,873
Other equity instruments redeemed ³	—	(15,661)	—	—	—	—	—	—	(15,661)	—	(15,661)
Dividends to shareholders ⁵	—	—	(109,776)	—	—	—	—	—	(109,776)	(4,844)	(114,620)
Movement in respect of share-based payment arrangements	—	—	(212)	—	—	—	—	(252)	(464)	10	(454)
Transfers and other movements ⁶	—	—	(2,247)	(4,098)	8	(1)	—	5,746	(592)	(2,835)	(3,427)
At 31 Dec 2024	180,181	64,677	471,198	61,204	424	710	(65,392)	106,047	819,049	58,959	878,008

1 Ordinary share capital includes preference shares which have been redeemed or bought back via payments out of distributable profits in previous years.

2 During 2025, additional tier 1 capital instruments amounting to US\$3,500m were issued with an issuance cost of US\$35m and an additional tier 1 capital instrument amounting to SG\$800m was issued with an issuance cost of SG\$8m.

During 2024, additional tier 1 capital instruments amounting to SG\$1,500m were issued with an issuance cost of SG\$15m and an additional tier 1 capital instrument amounting to US\$2,500m was issued with an issuance cost of US\$25m.

3 During 2025, an additional tier 1 capital instrument was redeemed at par (US\$2,200m).

During 2024, an additional tier 1 capital instrument was redeemed at par (US\$2,000m).

4 The other reserves mainly comprise share of associates' other reserves, purchase premium arising from transfer of business from fellow subsidiaries, property revaluation reserve relating to transfer of properties to a fellow subsidiary and the share-based payment reserve. The share-based payment reserve is used to record the amount relating to share awards and options granted to employees of the group directly by HSBC Holdings plc.

5 Including distributions paid on perpetual subordinated loans classified as equity under HKFRS.

6 The movements between retained earnings and other reserves include the relevant transfers to other reserves according to local regulatory requirements and transfers on dilution of interest in foreign operations. The transfer from the property revaluation reserve to retained earnings represents depreciation of revalued properties.

Consolidated Financial Statements

Consolidated statement of cash flows for the year ended 31 December

	2025 HK\$m	2024 HK\$m
Profit before tax	149,610	153,932
Adjustments for non-cash items:		
Depreciation, amortisation and impairment	17,110	19,597
Net loss from investing activities ¹	9,699	1,022
Share of profit in associates and joint ventures	(16,761)	(17,775)
Impairment of interest in associate ²	8,270	—
Change in expected credit losses gross of recoveries and other credit impairment charges	13,862	12,803
Provisions	832	584
Share-based payment expense	1,187	968
Other non-cash items included in profit before tax	(26,182)	(32,152)
Elimination of exchange differences	(40,690)	44,740
Changes in operating assets and liabilities		
Change in net trading securities and derivatives	(84,462)	(233,299)
Change in loans and advances to banks and customers	(173,393)	74,347
Change in reverse repurchase agreements – non-trading	(50,313)	(32,957)
Change in financial assets designated and otherwise mandatorily measured at fair value through profit or loss	(144,072)	(77,256)
Change in other assets	(62,849)	(32,822)
Change in deposits by banks and customer accounts	581,715	302,457
Change in repurchase agreements – non-trading	(2,033)	102,800
Change in debt securities in issue	(17,342)	(23,383)
Change in financial liabilities designated at fair value	16,460	8,011
Change in other liabilities	117,158	62,226
Dividends received from associates	5,930	5,930
Contributions paid to defined benefit plans	(247)	(332)
Tax paid	(22,898)	(34,908)
Net cash from operating activities	280,591	304,533
Purchase of financial investments	(2,644,600)	(2,883,041)
Proceeds from the sale and maturity of financial investments	2,606,989	2,569,243
Purchase of property, plant and equipment	(2,332)	(2,077)
Proceeds from sale of property, plant and equipment and assets held for sale	68	37
Net investment in intangible assets	(11,325)	(10,765)
Net cash (outflow)/inflow from increases in interest in associate and joint venture and purchase of business	(155)	4,821
Net cash inflow/(outflow) from disposal of businesses, associate and joint venture	192	(1,750)
Net cash outflow on purchase of subsidiaries	—	(345)
Net cash from investing activities	(51,163)	(323,877)
Issue of other equity instruments	31,686	27,873
Redemption of other equity instruments	(17,205)	(15,661)
Net cash outflow from change in stake of subsidiary	(1,196)	(3,006)
Subordinated loan capital issued ³	47,471	4,398
Subordinated loan capital repaid ³	(41,581)	(9,733)
Dividends paid to shareholders of the parent company and non-controlling interests	(99,010)	(114,620)
Net cash from financing activities	(79,835)	(110,749)
Net increase/(decrease) in cash and cash equivalents	149,593	(130,093)
Cash and cash equivalents at 1 Jan	823,249	996,638
Exchange differences in respect of cash and cash equivalents	27,200	(43,296)
Cash and cash equivalents at 31 Dec⁴	1,000,042	823,249
Cash and cash equivalents comprise		
– cash and balances at central banks	204,345	211,047
– loans and advances to banks of one month or less	324,056	295,345
– net settlement accounts, cash collateral and items in course of collection from/transmission to other banks	56,571	(3,901)
– reverse repurchase agreements with banks of one month or less	190,642	166,961
– treasury bills, other bills and certificates of deposit less than three months	224,326	153,797
– cash and cash equivalents held for sale	102	—
Cash and cash equivalents at 31 Dec⁴	1,000,042	823,249

Interest received was HK\$295,414m (2024: HK\$323,758m), interest paid was HK\$169,533m (2024: HK\$211,163m) and dividends received were HK\$11,419m (2024: HK\$11,232m).

- Amount in 2025 includes a loss of HK\$8,955 inclusive of reserves recycling as a result of the dilution of our shareholding in BoCom.
- Amount in 2025 includes a HK\$8,270m impairment loss following an impairment test on the carrying amount of the group's investment in BoCom.
- Changes in subordinated loan capital (including those issued to Group companies) during the year included amounts from issuance and repayments as presented above, and non-cash changes from foreign exchange loss of HK\$3,455m in 2025 (2024: exchange gain of HK\$2,466m) and fair value loss after hedging of HK\$6,093m in 2025 (2024: HK\$1,105m gain). These balances are presented under 'Amounts due to Group companies' in the consolidated balance sheet.
- At 31 December 2025, HK\$263,929m (2024: HK\$137,500m) was not available for use by the group due to a range of restrictions, including currency exchange and other restrictions. This includes HK\$74,771m (2024: Nil) segregated for Hang Seng Bank Limited privatisation funding purpose. Refer Note 39 for more details.

PARTIES

REGISTERED OFFICE OF THE ISSUER

The Hongkong and Shanghai Banking Corporation Limited
HSBC Main Building
1 Queen's Road Central
Hong Kong

LIQUIDITY PROVIDER

HSBC Securities Brokers (Asia) Limited
Levels 17 and 18
HSBC Main Building
1 Queen's Road Central
Hong Kong

INDEPENDENT AUDITOR

PricewaterhouseCoopers
Certified Public Accountants
Registered Public Interest Entity Auditor
22nd Floor, Prince's Building
Central
Hong Kong